A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 925-930

  Shamash, Jonathan ^a   Powles, T ^a   Mutsvangwa, K ^a   Wilson, P ^a   Ansell, W ^a   Walsh, E ^a   Berney, D ^a   Stebbing, J ^a   Oliver, T ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Germ cell tumour; Mediastinal; Phase 2; Relapsed

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHLORPHENIRAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; FOLLOW UP; GERM CELL TUMOR; GONAD TUMOR; HUMAN; INFECTION; KAPLAN MEIER METHOD; LETHARGY; MEDIASTINUM CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 34447337007     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm002     Document Type: Article

References (23)

1. Loehrer PJ, Einhorn LH, Williams SD. VP-16 ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986; 4: 528-536.
2. Loehrer PJ Sr, Genin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J Clin Oncol 1998; 16 (7): 2500-2504.
3. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumours. J Clin Oncol 2005; 23 (27): 6549-6555.
4. Bhatia S, Abonour R, Porcu P et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18 (19): 3346-3351.
5. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumour patients [see comment]. J Clin Oncol 2000; 18 (6): 1173-1180.
6. Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumours (E9897): A trial of the Eastern Cooperative Oncology Group [see comment] [Erratum appears in J Clin Oncol 2002; 20 (17): 3754]. J Clin Oncol 2002; 20 (7): 1859-1863.
7. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20 (8): 2031-2037.
8. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22 (1): 108-114.
9. Pectasides D, Pectasides M, Farmakis D et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumours: A phase II study. Ann Oncol 2004; 15 (3): 493-497.
10. De Giorgi U, Rosti G, Aieta M et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory non-seminomatous germ cell tumor. Eur Urol 2006; 50 (5): 1032-1038.
11. Broun ER, Nichols CR, Einhorn LH, Tricot GJ. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumours. Cancer 1991; 68 (7): 1513-1515.
12. Berney DM, Shamash J, Gaffney J et al. DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer 2002; 87 (6): 624-629.
13. Kollmannsberger C, Rick O, Klaproth H et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: A phase II study of the German Testicular Cancer Study Group [see comment]. Br J Cancer 2002: 87 (7): 729-732.
14. Miki T, Mizutani Y, Nonomura N et al. Irinotecan plus cisplatin has substantial antitumour effect as salvage chemotherapy against germ cell tumours. Cancer 2002; 95 (9): 1879-1885.
15. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumour patients: A phase II study. Eur Urol 2004; 46 (2): 216-221.
16. Dunn TA, Schmoll HJ, Grunwald V et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15 (2): 109-114.
17. Seidman A, Berry D, Cirrincione C et al. Phase II study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for trastuzumab in HER2 normal MBC. Proc Am Soc Clin Oncol 2004; 22 (6s Suppl): 6 (Abstr 512).
18. Rodenhuis S, de Wit R, de Mulder P et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999; 10 (12): 1467-1473.
19. Shamash J, Oliver RT, Ong J et al. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol 1999; 10 (6): 685-692.
20. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumours: A multivariate analysis of prognostic variables. J Clin Oncol 1996; 14 (10): 2638-2645.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Bedano P, Brames M, Williams S, Einhorn L. A phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumours J Clin Oncol 2006; 24 (34): 5403-5407.
23. Hartmann JT, Einhorn L, Nichols CR et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumours: results of an international multicenter analysis. J Clin Oncol 2001; 19 (6): 1641-1648.